topotecan has been researched along with Cancer of Prostate in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budillon, A; Caliendo, G; De Angelis, F; Di Cintio, A; Di Gennaro, E; Esposito, A; Fiorino, F; Frecentese, F; Incisivo, GM; Magli, E; Massarelli, P; Nencini, C; Perissutti, E; Santagada, V; Severino, B | 1 |
| Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L | 1 |
| Chow, A; Emmenegger, U; Francia, G; Kerbel, RS; Man, S; Wong, A | 1 |
| Blakely, K; Chow, A; Emmenegger, U; Goda, T; Hoang, VC; Liu, SK; Rocha, M; Taeb, S; Tran, E; Wong, A | 1 |
| Castellon, EA; Castillo, V; Contreras, HR; Huidobro, C; Valenzuela, R | 1 |
| Aljuffali, IA; Arnold, RD; Costyn, LJ; Cummings, BS; Mock, JN; Nagy, T; Nguyen, H | 1 |
| Jalota-Badhwar, A; Joshi, KS; Kumar, S; Manohar, SM; Padgaonkar, AA; Rathos, MJ; Sonawane, V | 1 |
| Cui, J; Li, C; Wang, C; Wei, N; Yang, H; Zhao, X | 1 |
| Durity, M; Hörmann, V; Kumi-Diaka, J; Rathinavelu, A | 1 |
| Dhandayuthapani, S; Gantar, M; Rathinavelu, A | 1 |
| Braun, TJ; Crawford, ED; Dakhil, SR; Hussain, MH; Klein, CE; Nichols, CR; Peereboom, DM; Rivkin, SE; Tangen, CM | 1 |
| Bucci, F; Carenini, N; Carminati, P; De Cesare, M; Gatti, L; Martinelli, R; Perego, P; Pisano, C; Pratesi, G; Supino, R; Zanier, R; Zuco, V; Zunino, F | 1 |
| Griffith, TS; Kemp, TJ | 1 |
| Aller, A; Andreotti, P; Caceres, G; Jiao, JA; Wong, H; Zankina, R; Zhu, X | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Balsari, A; Besusso, D; Maggi, R; Ménard, S; Petrangolini, G; Pratesi, G; Sfondrini, L; Tortoreto, M | 1 |
| Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH | 1 |
| Carenini, N; Ciusani, E; Corna, E; Gatti, L; Perego, P; Zunino, F | 1 |
| Benz, CC; Conrad, F; Drummond, DC; Hayes, ME; Kirpotin, DB; Liu, B; Marks, JD; Roth, A | 1 |
| Fox, SC; Giantonio, BJ; Greenberg, R; Hudes, GR; Kosierowski, R; McAleer, CA; Ozols, RF; Ramsey, HE | 1 |
2 trial(s) available for topotecan and Cancer of Prostate
| Article | Year |
|---|---|
SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Middle Aged; Prostatic Neoplasms; Survival Analysis; Topotecan; Treatment Outcome | 2002 |
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostatic Neoplasms; Topotecan; Treatment Outcome | 1995 |
18 other study(ies) available for topotecan and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Ligands; Male; Molecular Structure; Naphthalenes; Piperazines; Prostatic Neoplasms; Receptor, Serotonin, 5-HT1A; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Camptothecins in tumor homing via an RGD sequence mimetic.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats | 2012 |
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fecal Impaction; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Taxoids; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Prostatic Neoplasms; Radiation Tolerance; Taxoids; Topotecan | 2013 |
Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Neoplasm Proteins; Neoplastic Stem Cells; Prostatic Neoplasms; Spheroids, Cellular; Topotecan; Tumor Cells, Cultured | 2014 |
Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.
Topics: Animals; Annexin A5; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Humans; Male; Mice; Mice, Nude; Mitochondria; Prostatic Neoplasms; Topotecan; Tumor Suppressor Protein p53 | 2011 |
A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
Topics: Angiogenesis Inhibitors; Animals; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Pyridines; Pyrimidines; Signal Transduction; Topotecan; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma, Lewis Lung; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Hand-Foot Syndrome; Humans; Injections, Intravenous; Leukemia L1210; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Rats; Rats, Wistar; Skin; Skin Diseases; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan | 2012 |
Anticancer activities of genistein-topotecan combination in prostate cancer cells.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Culture Media; DNA Fragmentation; Enzyme Activation; Genistein; Humans; Male; Prostatic Neoplasms; Reactive Oxygen Species; Topotecan | 2012 |
Phycocyanin induces apoptosis and enhances the effect of topotecan on prostate cell line LNCaP.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; DNA Fragmentation; Humans; Male; Phycocyanin; Prostatic Neoplasms; Reactive Oxygen Species; Spirulina; Topotecan | 2012 |
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA Damage; DNA, Neoplasm; Humans; Male; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Male; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Proteins; Prostatic Neoplasms; Survivin; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Luciferases; Male; Mice; Prostatic Neoplasms; Topotecan; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon-gamma; Interleukin-12; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Oligodeoxyribonucleotides; Prostatic Neoplasms; Topotecan; Transplantation, Heterologous; Weight Loss | 2004 |
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha | 2004 |
Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Gene Silencing; Genetic Vectors; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transfection; Tumor Necrosis Factor-alpha; Up-Regulation | 2006 |
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
Topics: Activated-Leukocyte Cell Adhesion Molecule; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Communication; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Flow Cytometry; Humans; Immunoglobulin Fragments; Ligands; Liposomes; Male; Prostatic Neoplasms; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 2007 |